Cardiovascular risk assessment using the lipid accumulation product index among primary healthcare users

a cross-sectional study

Autores

Palavras-chave:

Obesity, Overweight, Cardiovascular diseases, Primary health care, Waist circumference

Resumo

BACKGROUND: The lipid accumulation product (LAP) index is an abdominal adiposity marker. OBJECTIVE: The aim of this study was to describe the cardiovascular risk of primary healthcare users through the LAP index and correlate it with anthropometric and biochemical indicators. DESIGN AND SETTING: Cross-sectional study in primary care units in a city in northeastern Brazil. METHODS: The subjects responded to a structured questionnaire that contained questions about their sociodemographic condition, and then underwent an anthropometric nutritional assessment. The LAP index values were expressed as three degrees of cardiovascular risk intensity: high risk (above the 75th percentile), moderate risk (between the 25th and 75th percentiles) and low risk (below the 25th percentile). RESULTS: The median LAP index was 52.5 cm.mmol/l (range: 28.2-86.6), and there was no statistically significant difference between the sexes: 57.7 cm.mmol/l (24.5-91.1) and 49.5 cm.mmol/l (29.8-85.2) for females and males, respectively (P = 0.576). Among all the subjects, 67.2% were overweight and there was a statistically significant difference in mean LAP index between those who were and those who were not overweight. Statistically significant differences in anthropometric and biochemical markers for cardio-vascular risk were observed among individuals who had higher LAP index values. There were significant correlations between the LAP index and all of the biochemical variables. CONCLUSIONS: These significant correlations between the LAP index and the traditional biochemical risk markers may be useful within conventional clinical practice, for cardiovascular risk screening in pri-mary healthcare.

Downloads

Não há dados estatísticos.

Biografia do Autor

Jallyne Nunes Vieira, Universidade Federal do Rio Grande do Norte (UFRN)

Undergraduate Student at Health Science College of Trairi, Universidade Federal do Rio Grande do Norte (UFRN), Santa Cruz (RN), Brazil. orcid.org/0000-0002-4681-8145

Marina Augusta Dias Braz, Universidade Federal do Rio Grande do Norte (UFRN)

Undergraduate Student at Health Science College of Trairi, Universidade Federal do Rio Grande do Norte  (UFRN), Santa Cruz, RN, Brazil.  orcid.org/0000-0002-8298-1687

Flayane Oliveira Gomes, Universidade Federal do Rio Grande do Norte (UFRN)

Undergraduate Student at Health Science College of Trairi, Universidade Federal do Rio Grande do Norte (UFRN), Santa Cruz (RN), Brazil.  orcid.org/0000-0002-7211-4598

Priscilla Rafaella da Silva, Universidade Federal do Rio Grande do Norte (UFRN)

Undergraduate Student at Health Science College of Trairi, Universidade Federal do Rio Grande do Norte (UFRN), Santa Cruz (RN), Brazil.  orcid.org/0000-0001-9355-6144

Ohanna Thays de Medeiros Santos, Universidade Federal do Rio Grande do Norte (UFRN)

Undergraduate Student at Health Science College of Trairi, Universidade Federal do Rio Grande do Norte (UFRN), Santa Cruz (RN), Brazil.  orcid.org/0000-0001-7925-9928

Ilanna Marques Gomes da Rocha, Universidade Federal do Rio Grande do Norte (UFRN)

BSc. Master’s Degree Student in Postgraduate Program on Nutrition, Health Science Center, Universidade Federal do Rio Grande do Norte (UFRN), Natal (RN), Brazil.  orcid.org/0000-0003-2945-6872

Iasmin Matias de Sousa, Universidade Federal do Rio Grande do Norte (UFRN)

BSc. Master’s Degree Student in Postgraduate Program on Nutrition, Health Science Center, Universidade Federal do Rio Grande do Norte (UFRN), Natal (RN), Brazil.  orcid.org/0000-0001-6076-3024

Ana Paula Trussardi Fayh, Universidade Federal do Rio Grande do Norte (UFRN)

PhD. Professor of Postgraduate Program on Nutrition, Health Science Center, Universidade Federal do Rio Grande do Norte (UFRN), Natal (RN), Brazil.  orcid.org/0000-0002-9130-9630

Referências

World Health Organization. Cardiovascular diseases (CVDs). Available from: http://www.who.int/mediacentre/factsheets/fs317/en/. Accessed in 2018 (Jul 23).

World Health Organization. Obesity and overweight. Available from: http://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Accessed in 2018 (Jul 23).

Schneider HJ, Glaesmer H, Klotsche J, et al. Accuracy of anthropometric indicators of obesity to predict cardiovascular risk. J Clin Endocrinol Metab. 2007;92(2):589-94. PMID: 17105840; doi: 10.1210/jc.2006-0254.

Roriz AKC, Passos LCS, de Oliveira CC, et al. Evaluation of the accuracy of anthropometric clinical indicators of visceral fat in adults and elderly. PLoS One. 2014;9(7):e103499. PMID: 25078454; doi: 10.1371/journal. pone.0103499.

Lee CM, Huxley RR, Wildman RP, Woodward M. Indices of abdominal obesity are better discriminators of cardiovascular risk factors than BMI: a meta-analysis. J Clin Epidemiol. 2008;61(7):646-53. PMID: 18359190; doi: 10.1016/j.jclinepi.2007.08.012.

Wakabayashi I, Daimon T. A strong association between lipid accumulation product and diabetes mellitus in Japanese women and men. J Atheroscler Thromb. 2014;21(3):282-8. PMID: 24304961; doi: 10.5551/jat.20628.

Vieira BA, Sauer P, Marcadenti A, Piovesan CH. Association between LAP index (lipid accumulation product) and metabolic profile in hospitalized patients. Nutr Hosp. 2015;31(6):2771-4. PMID: 26040394; doi: 10.3305/ nh.2015.31.6.8957.

Ioachimescu AG, Brennan DM, Hoar BM, Hoogwerf BJ. The lipid accumulation product and all-cause mortality in patients at high cardiovascular risk: a PreCIS database study. Obesity (Silver Spring). 2010;18(9):1836-44. PMID: 20035284; doi: 10.1038/oby.2009.453.

Kahn HS. The “lipid accumulation product” performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison. BMC Cardiovasc Disord. 2005;5:26. PMID: 16150143; doi: 10.1186/1471-2261-5-26.

Mario FM, Graff SK, Spritzer PM. Adiposity Indexes as Phenotype-Specific Markers of Preclinical Metabolic Alterations and Cardiovascular Risk in Polycystic Ovary Syndrome: A Cross-Sectional Study. Exp Clin Endocrinol Diabetes. 2017;125(5):307-15. PMID: 28201826; doi: 10.1055/ s-0042‑119524.

Costa EC, Sá JC, Soares EM, Lemos TM, Maranhão TM, Azevedo GD. Avaliação do risco cardiovascular por meio do índice LAP em pacientes não obesas com síndrome dos ovários policísticos [Evaluation of cardiovascular risk by the LAP index in non-obese patients with polycystic ovary syndrome]. Arq Bras Endocrinol Metabol. 2010;54(7):630-5. PMID: 21085768; doi: 10.1590/S0004-27302010000700007.

de Oliveira C, Roriz A, Ramos LB, Gomes Neto M. Indicators of Adiposity Predictors of Metabolic Syndrome in the Elderly. Ann Nutr Metab. 2017;70(1):9-15. PMID: 28103600; doi: 10.1159/000455333.

Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal, 2016;37(29):2315-2381. PMID: 27692125. doi: 10.1093/ eurheartj/ehw106.

Associação Brasileira de Empresas de Pesquisa (ABEP). Critério de classificação econômica do Brasil. Available from: www.abep.org/ Servicos/Download.aspx?id=07. Accessed in 2018 (Jul 24).

Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-97. PMID: 11368702; doi: 10.1001/jama.285.19.2486.

D’Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743-53. PMID: 18212285. doi: 10.1161/ CIRCULATIONAHA.107.699579.

Conroy RM, Pyörälä K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24(11):987-1003. PMID: 12788299.

Giampaoli S. CUORE: a sustainable cardiovascular disease prevention strategy. Eur J Cardiovasc Prev Rehabil. 2007;14(2):161-2. PMID: 17446792. doi: 10.1097/HJR.0b013e328157f3e5.

Xie X, Li Q, Zhang L, Ren W. Lipid accumulation product, visceral adiposity index, and Chinese visceral adiposity index as markers of cardiometabolic risk in adult growth hormone deficiency patients: a cross-sectional study. Endocr Pract. 2018;24(1):33-9. PMID: 29144802. doi: 10.4158/EP-2017-0007.

Chiang JK, Koo M. Lipid accumulation product: a simple and accurate index for predicting metabolic syndrome in Taiwanese people aged 50 and over. BMC Cardiovasc Disord. 2012;12:78. PMID: 23006530; doi: 10.1186/1471-2261-12-78.

Nascimento JX, Chein MB, de Sousa RM, et al. Importance of lipid accumulation product index as a marker of CVD risk in PCOS women. Lipids Health Dis. 2015;14:62. PMID: 26104466; doi: 10.1186/s12944-015-0061-y.

Du T, Yu X, Zhang J, Sun X. Lipid accumulation product and visceral adiposity index are effective markers for identifying the metabolically obese normal-weight phenotype. Acta Diabetol. 2015;52(5):855-63. PMID: 25690647; doi: 10.1007/s00592-015-0715-2.

Xia C, Li R, Zhang S, et al. Lipid accumulation product is a powerful index for recognizing insulin resistance in non-diabetic individuals. Eur J Clin Nutr. 2012;66(9):1035-8. PMID: 22781025; doi: 10.1038/ejcn.2012.83.

Downloads

Publicado

2019-04-04

Como Citar

1.
Vieira JN, Braz MAD, Gomes FO, Silva PR da, Santos OT de M, Rocha IMG da, Sousa IM de, Fayh APT. Cardiovascular risk assessment using the lipid accumulation product index among primary healthcare users: a cross-sectional study. Sao Paulo Med J [Internet]. 4º de abril de 2019 [citado 14º de março de 2025];137(2):126-31. Disponível em: https://periodicosapm.emnuvens.com.br/spmj/article/view/815

Edição

Seção

Artigo Original